Clarivate to Sell Life Sciences & Healthcare Unit for $600 Million and Reduce Debt
CLVT•Clarivate has agreed to divest its Life Sciences & Healthcare segment for $600 million, receiving $500 million at closing, $25 million deferred and a $75 million seller note. Proceeds will reduce debt, improve revenue mix, expand adjusted EBITDA margins and sharpen focus on Academia & Government and Intellectual Property segments.
1. Transaction Details
Clarivate has entered a definitive agreement to sell its Life Sciences & Healthcare segment to Altaris for $600 million, comprising $500 million in cash at closing, a $25 million deferred payment under a transition services agreement and a $75 million seller note. The divestiture is subject to regulatory approvals and is expected to close by year-end.
2. Financial Impact
Net proceeds from the sale will be allocated to debt reduction, strengthening the balance sheet and lowering capital intensity. Management projects the transaction will enhance adjusted EBITDA margins and improve the quality of recurring revenue by refocusing on subscription-based businesses.
3. Strategic Refocus
Post-transaction, Clarivate will concentrate on its Academia & Government and Intellectual Property segments, leveraging shared content assets and technology platforms. Leadership expects this leaner portfolio to drive innovation, streamline execution and unlock shareholder value through differentiated insights and workflow solutions.
4. Outlook and Timeline
Clarivate reaffirmed its full-year 2026 guidance, incorporating the Life Sciences & Healthcare results as discontinued operations in Q3 and anticipating a $225 million–$250 million non-cash goodwill impairment. A conference call and webcast is scheduled to review the transaction at 9:00 a.m. ET today.
